AstraZeneca has ended its partnership with US "rent-a-rep" organization PDI, potentially wiping a massive $65-$70 million from the latter's sales this year.
According to PDI, termination of the contract - as of April 30 - will have a significant financial impact on 2006, and will affect around 800 field representatives.
Add this to the news about the hundreds of reps recently given notice by BMS and it looks like the cold cold wind has started to blow thru Big Pharmas' sales organizations.
Not good for morale and motivation.
No comments:
Post a Comment